<DOC>
	<DOCNO>NCT00607672</DOCNO>
	<brief_summary>Each year million patient worldwide undergo cardiac surgery require cardiopulmonary bypass ( CPB ) .1 CPB associate significant morbidity include hemodynamic instability , transfusion allogenic blood product , inflammation . Blood product transfusion increase mortality cardiac surgery . Enhanced fibrinolysis contributes increase blood product transfusion requirement perioperative period . CPB activate kallikrein-kinin system ( KKS ) , lead increase bradykinin concentration . Bradykinin , act B2 receptor , stimulate release nitric oxide , inflammatory cytokine tissue-type plasminogen activator ( t-PA ) . Based data indicate angiotensin-converting enzyme ( ACE ) inhibitor reduce mortality patient coronary artery disease , many patient undergo CPB take ACE inhibitor . While interruption renin-angiotensin system ( RAS ) reduce inflammation response CPB , ACE inhibitor also potentiate effect bradykinin may augment B2-mediated change fibrinolytic balance inflammation . In contrast , angiotensin II type 1 receptor antagonism potentiate bradykinin inhibit bradykinin metabolism . Studies animal suggest bradykinin receptor antagonism inhibit reperfusion-induced increase vascular permeability neutrophil recruitment.A randomize , placebo control clinical trial bradykinin B2 receptor antagonist demonstrate effect survival patient systemic inflammatory response syndrome gram-negative sepsis . In addition , others show bradykinin B2 receptor antagonism reduce vascular t-PA release ACE inhibition . The current proposal derive data laboratory others elucidate role KKS inflammatory , hypotensive fibrinolytic response CPB . Specifically , find CPB activates KKS ACE inhibition smoking increase bradykinin concentration . During CPB , bradykinin concentration correlate inversely mean arterial pressure directly t-PA . Moreover , find bradykinin receptor antagonism attenuate protamine-related hypotension follow CPB . The current proposal test central hypothesis fibrinolytic inflammatory response cardiopulmonary bypass differ angiotensin-converting enzyme inhibition angiotensin II type 1 receptor antagonism .</brief_summary>
	<brief_title>The RAS , Fibrinolysis Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects , 18 80 year age , schedule elective cardiac surgery require CPB 2 . For female subject , follow condition must meet : postmenopausal least 1 year , statuspost surgical sterilization , childbearing potential , utilizing adequate birth control willing undergo urine betahcg test prior drug treatment every study day 1 . Left ventricle ejection fraction le 30 % 2 . History ACE inhibitorinduced angioedema 3 . Hypotension ( systolic blood pressure &lt; 100 mmHg evidence hypoperfusion ) 4 . Hyperkalemia ( baseline potassium &gt; 5.0 mEq/L ) 5 . Inability discontinue current ACE inhibitor AT1 receptor antagonist . 6 . Emergency surgery 7 . Impaired renal function ( serum creatinine &gt; 1.6 mg/dl ) 8 . Pregnancy 9 . Breastfeeding 10 . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult 11 . History alcohol drug abuse 12 . Treatment investigational drug 1 month precede study 13 . Mental condition render subject unable understand nature , scope possible consequence study 14 . Inability comply protocol , e.g . uncooperative attitude unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Angiotensin Converting Enzyme</keyword>
	<keyword>Angiotensin Receptor Blockers</keyword>
	<keyword>Cardiopulmonary Bypass</keyword>
	<keyword>Fibrinolysis</keyword>
	<keyword>Inflammation</keyword>
</DOC>